Amarna Therapeutics B.V. Teaming Up with Austrian CBmed In The Development Of Immunotherapies
Leiden, The Netherlands, Graz, Austria, June 29, 2015 / B3C newswire / -- Dutch Amarna Therapeutics
The agreement includes the design, development and testing in two separate projects of a CAR T-cell therapy and reverse vaccines for the treatment of these major diseases with high unmet clinical needs. Amarna will contribute its proprietary SVac viral gene delivery vector platform
Immunotherapies hold an enormous potential as novel treatment options for a wide range of diseases, including cancer and degenerative diseases such as obesity, DM2 and ASCVD. The objective of this collaboration is to test Amarna’s SVac vector platform for its capacity to modulate immune responses in humans with the final aim to develop efficient treatment options for cancer, diabetes and cardiovascular diseases.
Ben van Leent, CEO of Amarna: "We are excited to extend our pipeline of products and launch activities in these important disease areas. We are convinced that the combination of the technology platform from Amarna Therapeutics and the scientific and medical expertise of CBmed will lead to the development of breakthrough solutions for a large group of immunity-associated diseases.”
Thomas Pieber, CSO of CBmed: "Biomarkers play a crucial role in the development of new therapeutic and preventive agents. This cooperation is a wonderful opportunity for CBmed to investigate novel biomarkers alongside the identification of new therapeutic targets for the innovative treatment approaches of Amarna Therapeutics."
About CAR T-cell therapy
In CAR T-cell therapies, engineered chimeric antigen receptors (CARs) with specificity for a tumor-specific cell surface protein (tumor antigen) are transferred to CD8+ T cells sampled from cancer patients. The CD8+ T cells expressing the CARs will specifically target and destroy the patient’s tumor cells, thereby attempting to cure the patient from cancer. In this collaboration, an SVac vector encoding a CAR which is specific for CD19 and present on B-cells, will be tested for its efficacy to treat ALL as a proof-of-principle for SVac-based CAR T-cell therapies to treat cancer.
About SVac-based reverse vaccines
About Amarna Therapeutics
About CBmed
CBmed, a multidisciplinary competence center for biomarker research in medicine is located in Graz, Austria. CBmed links excellent preclinical and clinical research infrastructure with scientific and medical expertise through interdisciplinary projects led by experienced researchers and clinicians from national and international universities and research institutions.
In one of CBmed’s core laboratories, state-of-the-art immunological assays are developed and used to monitor human cellular immune responses and to characterize immune cells involved in autoinflammation. The linked animal facility and the tight collaboration with the Medical Universities in Graz and Vienna and the Biobank Graz subsequently allow the rapid translation of in vitro findings into preclinical and clinical in vivo research.
Help employers find you! Check out all the jobs and post your resume.
The agreement includes the design, development and testing in two separate projects of a CAR T-cell therapy and reverse vaccines for the treatment of these major diseases with high unmet clinical needs. Amarna will contribute its proprietary SVac viral gene delivery vector platform
Immunotherapies hold an enormous potential as novel treatment options for a wide range of diseases, including cancer and degenerative diseases such as obesity, DM2 and ASCVD. The objective of this collaboration is to test Amarna’s SVac vector platform for its capacity to modulate immune responses in humans with the final aim to develop efficient treatment options for cancer, diabetes and cardiovascular diseases.
Ben van Leent, CEO of Amarna: "We are excited to extend our pipeline of products and launch activities in these important disease areas. We are convinced that the combination of the technology platform from Amarna Therapeutics and the scientific and medical expertise of CBmed will lead to the development of breakthrough solutions for a large group of immunity-associated diseases.”
Thomas Pieber, CSO of CBmed: "Biomarkers play a crucial role in the development of new therapeutic and preventive agents. This cooperation is a wonderful opportunity for CBmed to investigate novel biomarkers alongside the identification of new therapeutic targets for the innovative treatment approaches of Amarna Therapeutics."
About CAR T-cell therapy
In CAR T-cell therapies, engineered chimeric antigen receptors (CARs) with specificity for a tumor-specific cell surface protein (tumor antigen) are transferred to CD8+ T cells sampled from cancer patients. The CD8+ T cells expressing the CARs will specifically target and destroy the patient’s tumor cells, thereby attempting to cure the patient from cancer. In this collaboration, an SVac vector encoding a CAR which is specific for CD19 and present on B-cells, will be tested for its efficacy to treat ALL as a proof-of-principle for SVac-based CAR T-cell therapies to treat cancer.
About SVac-based reverse vaccines
About Amarna Therapeutics
About CBmed
Help employers find you! Check out all the jobs and post your resume.